Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Scientists describe the mechanisms that regulate embryonic stem cells

Scientists at the Proteomics Core Unit of the Spanish National Cancer Research Centre (CNIO), headed by Javier Muñoz, have described the mechanisms, unknown to date, involved in maintaining embryonic stem cells in the best possible state for their use in regenerative medicine.

26 Mar 2021

Researchers identify epigenetic mechanism responsible for lifelong stress susceptibility

An epigenetic modification that occurs in a major cell type in the brain's reward circuitry controls how stress early in life increases susceptibility to additional stress in adulthood, researchers at the Icahn School of Medicine at Mount Sinai have learned.

15 Mar 2021

Cancer cells may dodge chemotherapy by going into 'active hibernation'

Cancer cells can dodge chemotherapy by entering a state that bears similarity to certain kinds of senescence, a type of "active hibernation" that enables them to weather the stress induced by aggressive treatments aimed at destroying them, according to a new study by scientists at Weill Cornell Medicine.

13 Mar 2021

Whole genome sequencing may guide blood cancer treatment

For certain blood cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), deciding whether patients need an aggressive treatment typically hinges on a set of lab tests to identify genetic changes.

11 Mar 2021

New method boosts research efforts to eradicate cancer at its source

A new method, described in a study published today in the journal Nature Communications, has the potential to boost international research efforts to find drugs that eradicate cancer at its source.

1 Mar 2021

A new method for controlling leukemic stem cells

Leukemia is caused by leukemic stem cells which are resistant to most known therapies. Relapses are also due to this resistance. Leukemic stem cells arise from normal blood-forming (hematopoietic) stem cells.

17 Feb 2021

What are the changes in the physical phenotype of blood cells in COVID-19?

While primarily a respiratory illness, there are distinctive alterations in the type and number of blood cells in COVID-19. A new study by a team of researchers in Germany describes the nature of these changes.

16 Feb 2021

Gene panel is effective at identifying problematic genes in common leukemia

A gene panel that looks for about 10 times the number of cancer-causing genes as panels currently used to diagnose and fine-tune treatment for a variety of cancers is effective at identifying problematic genes in the most common leukemia, investigators report.

1 Feb 2021

Physicians receive Pfizer Prize for research on leukemia, cardiac arrhythmias

This year, four of a total of fifteen Pfizer Research Prizes have been awarded to physicians from the University of Bern and the Inselspital, University Hospital Bern.

28 Jan 2021

Innovative breakthrough promises to diagnose DNA rearrangement mutations

Doctors are increasingly using genetic signatures to diagnose diseases and determine the best course of care, but using DNA sequencing and other techniques to detect genomic rearrangements remains costly or limited in capabilities.

28 Jan 2021

Study uses computational framework to identify tamoxifen resistance markers in ER+ breast cancer

One common challenge of cancer therapy is when cancer cells don't respond to a drug that is usually able to kill or weaken them, known as treatment resistance.

26 Jan 2021

New maintenance treatment for AML shows strong benefit for patients

Patients with acute myeloid leukemia (AML), the most common form of acute leukemia in adults, that has gone into remission following initial chemotherapy remain in remission longer and have improved overall survival when they are given a pill form of the cancer drug azacitidine as a maintenance treatment, according to a randomized, international phase 3 clinical trial for which Weill Cornell Medicine and NewYork-Presbyterian are trial sites.

22 Jan 2021

New study helps understand molecular profile of tumors in cancer patients

Researchers from the University Hospitals in Zurich and Basel, ETH Zurich, University of Zurich and the pharmaceutical company Roche have set out to improve cancer diagnostics by developing a platform of state-of-the-art molecular biology methods.

21 Jan 2021

Investigational combo therapy shows promise in treating TP53 mutant MDS and AML patients

Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow.

21 Jan 2021

Researchers identify new drug combination that can treat acute myeloid leukemia

Scientists have identified two drugs that are potent against acute myeloid leukemia (AML) when combined, but only weakly effective when used alone.

19 Jan 2021

IU research findings could prevent common complication of blood stem cell transplantation in leukemia

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center published promising findings today in the New England Journal of Medicine on preventing a common complication to lifesaving blood stem cell transplantation in leukemia.

7 Jan 2021

Study shows benefits of integrated palliative and oncology care for patients with advanced AML

A first-of-its-kind intervention integrating palliative care early in the course of cancer therapy for patients with advanced acute myeloid leukemia (AML), a highly aggressive cancer of the blood and bone marrow, resulted in substantial improvements in patients' quality of life, mood and end-of-life care, a team of investigators has found.

17 Dec 2020

Hematoxylin compounds can selectively kill CALR mutant cancer cells

Patients with myeloproliferative neoplasm (MPN), a group of malignant diseases of the bone marrow, often have a carcinogenic mutated form of the calreticulin gene (CALR).

10 Dec 2020

Phase I/IIA open-label study presents encouraging results on hard-to-treat AML subtypes

Novel menin-KMT2A inhibitor appears to be safe and well-tolerated. FLT3 inhibitor plus low-dose chemotherapy shows promising efficacy and safety. Results represent encouraging news on hard-to-treat AML subtypes.

7 Dec 2020

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.